GH Research Stock (NASDAQ:GHRS)
Previous Close
$6.53
52W Range
$5.05 - $14.99
50D Avg
$9.53
200D Avg
$9.83
Market Cap
$337.66M
Avg Vol (3M)
$40.35K
Beta
0.79
Div Yield
-
GHRS Company Profile
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
GHRS Performance
Peer Comparison
Ticker | Company |
---|---|
CYT | Cyteir Therapeutics, Inc. |
PMVP | PMV Pharmaceuticals, Inc. |
CGEM | Cullinan Oncology, Inc. |
IKNA | Ikena Oncology, Inc. |
RCUS | Arcus Biosciences, Inc. |
MLYS | Mineralys Therapeutics, Inc. |
STOK | Stoke Therapeutics, Inc. |
RLAY | Relay Therapeutics, Inc. |
CSBR | Champions Oncology, Inc. |
JANX | Janux Therapeutics, Inc. |
ANNX | Annexon, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
MNOV | MediciNova, Inc. |
DSGN | Design Therapeutics, Inc. |
PHVS | Pharvaris N.V. |
RZLT | Rezolute, Inc. |
GPCR | Structure Therapeutics Inc. |
HOWL | Werewolf Therapeutics, Inc. |
PEPG | PepGen Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
MOLN | Molecular Partners AG |
ELYM | Eliem Therapeutics, Inc. |